Publications

Clinical impact of visceral thrombosis (VT) in pancreatic ductal adenocarcinoma (PDAC).

A Mier Hicks, M Raj, RKG Do, KH Yu, MA Lowery, AM Varghese, ...

Do pancreas cancer stem cells play crucial role in survival outcome?

G Askan, IH Sahin, M Capanu, M Turkekul, KH Yu, MA Lowery, O Basturk, ...

Early-onset pancreatic ductal adenocarcinoma (PDAC) at Memorial Sloan Kettering Cancer Center (MSKCC).

S Kunte, S Sangli, A Lemor, MA Lowery, KH Yu, GK Abou-Alfa, ...

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic …

AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ...

First-in-human study of 89Zr-DFO-HuMab-5B1 (MVT-2163) PET/CT imaging with and without HuMab-5B1 (MVT-5873) in patients with pancreatic cancer and other CA 19-9 positive …

C Lohrmann, E O'Reilly, J ODonoghue, KH Yu, N Pandit-Taskar, ...

Hepatobiliary Cancer

GK Abou-Alfa, E O'Reilly

Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?

IH Sahin, G Askan, ZI Hu, EM O’Reilly

Impact of care at Memorial Sloan Kettering Cancer Center (MSKCC): A comprehensive cancer center on overall survival (OS) in patients (pts) with AJCC stage IV pancreas …

F Boland, A Cheema, MA Lowery, KH Yu, AM Varghese, AS Epstein, ...

Impact of early FDG-PET directed intervention on preoperative therapy for locally advanced gastric cancer: A Cooperative Group random assignment phase II study (Alliance …

MA Shah, Q Shi, VE Strong, J Strasser, DH Ilson, L Kleinberg, S Iqbal, ...

Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.

KA Goodman, D Niedzwiecki, N Hall, TS Bekaii-Saab, X Ye, MO Meyers, ...

Molecular landscape of fibrolamellar carcinoma (FLC): Beyond the DNAJB1-PRKACA chimera.

IH El Dika, M Capanu, MF Berger, ME Arcila, R Benayed, JJ Harding, ...

Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing

D Mandelker, L Zhang, Y Kemel, ZK Stadler, V Joseph, A Zehir, ...

Necuparanib combined with nab-paclitaxel+ gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results.

EM O'Reilly, D Mahalingam, JM Roach, PJ Miller, ME Rosano, S Krause, ...

Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients

M Dhir, GK Malhotra, DPS Sohal, NA Hein, LM Smith, EM O’Reilly, ...

Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer

T Golan, T Sella, EM O'Reilly, MHG Katz, R Epelbaum, DP Kelsen, ...

Pancreas adenocarcinoma: novel therapeutics

BA Krantz, HY Kenneth, EM O’Reilly

Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology

MA Tempero, MP Malafa, M Al-Hawary, H Asbun, A Bain, SW Behrman, ...

Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies

M Chiaravalli, M Reni, EM O'Reilly

Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC).

MA Lowery, JJ Harding, KH Yu, DP Kelsen, JS Bomalaski, DC Glassman, ...

Preface: pancreas adenocarcinoma

EM O'Reilly, L Zheng

Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients

J Chakraborty, L Langdon-Embry, KM Cunanan, JG Escalon, PJ Allen, ...

Prospective assessment for pathogenic germline alterations (PGA) in pancreas cancer (PAC).

E Jordan, MA Lowery, W Wong, Y Kemel, S Mukherjee, V Ravichandran, ...

Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite …

FA Sinicrope, FS Ou, Q Shi, AB Nixon, K Mody, A Levasseur, AC Dueck, ...

Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype

MA Lowery, EJ Jordan, O Basturk, RN Ptashkin, A Zehir, MF Berger, ...

Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+ Gem) in …

EM O'Reilly, V Sahai, JC Bendell, AJ Bullock, NK LoConte, H Hatoum, ...

Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: rationale and design of the CASSINI trial

AA Khorana, S Vadhan-Raj, NM Kuderer, T Wun, H Liebman, G Soff, ...

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab‐paclitaxel and gemcitabine in patients with metastatic pancreatic cancer …

EM O’Reilly, J Roach, P Miller, KH Yu, C Tjan, M Rosano, S Krause, ...

Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, in patients with pancreatic cancer and other CA19-9 positive malignancies.

EM O'Reilly, JSZ Wang, KH Yu, MA Lowery, AM Varghese, JC Bendell, ...

Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary (1o) tumor side.

L Furchtgott, D Swanson, B Hayete, I Khalil, D Wuest, K Rich, AB Nixon, ...

Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer

JJ Park, C Hajj, M Reyngold, W Shi, Z Zhang, JJ Cuaron, CH Crane, ...

Synthetic Lethality: Achilles Heel in Select Patient Subpopulations

MY Teo, EM O’Reilly

The oral microbiota in patients with pancreatic cancer, patients with IPMNs, and controls: a pilot study

SH Olson, J Satagopan, Y Xu, L Ling, S Leong, I Orlow, A Saldia, P Li, ...

Treatment of pancreatic cancer by intra-arterial injection of an emulsion of Lipiodol and bumetanide (an anti-glycolytic drug) in a porcine model: initial results

H Yarmohammadi, AG Aguirre, L Schook, E Ziv, J Erinjeri, K Brown, ...

Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux)+ capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure …

H Hurwitz, E Van Cutsem, JC Bendell, M Hidalgo, CP Li, M Garrido, ...

Understanding Pancreatic Cancer: National Pancreas Foundation's (NPF) Animated Pancreas Patient (APP): Informing Patients for Better Health Outcomes

S Munigala, E O'Reilly, M Alsante, J Holt, A Gelrud

Visceral thromboses (VT) in pancreas adenocarcinoma (PDAC): A systematic review.

A Mier Hicks, A Derosa, M Raj, RKG Do, KH Yu, MA Lowery, ...

A novel scoring system to predict survival in patients with advanced pancreatic adenocarcinoma: The Memorial Prognostic Score (MPS).

AC Yang, A Wiesenthal, AS Epstein, J Zheng, J Goldberg, J Meadows, ...

A phase 2, open-label, multicenter study of durvalumab (MEDI4736)±tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS.

EM O'Reilly, DY Oh, MA Lee, N Dhani, J Armstrong, R Belli, S Ferro, ...

Abstract CT026: Phase I trial of HuMab-5B1 (MVT-5873), a novel monoclonal antibody targeting sLea, in patients with advanced pancreatic cancer and other CA19-9 positive …

EM O’Reilly, TM Bauer, J Infante, JC Gutheil, P Klein, KH Yu, MA Lowery, ...

Abstract IA10: Biomarker selected therapy for pancreas ductal adenocarcinoma: an emerging reality?

EM O'Reilly

Adjuvant and neoadjuvant therapy for pancreatic cancer

D Li, EM O’Reilly

An atypical initial presentation of hepatocellular carcinoma as spinal cord compression

S Sangli, PK Mankal, E Fowle, J Abed, E O’Reilly, DP Kotler

APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected …

MA Tempero, DB Cardin, D Goldstein, EM O'Reilly, PA Philip, H Riess, ...

Assessment of genomic alterations in adenosquamous carcinoma of the pancreas (ASCOP).

E Jordan, O Basturk, SD Leach, DS Klimstra, PJ Allen, MF Berger, ...

Breast cancer resistance protein (ABCG2) as a potential biomarker for gemcitabine and nab-paclitaxel sensitivity.

KH Yu, M Ricigliano, EM O'Reilly, MA Lowery, B Cooper, CM Covington

Clinical and Molecular Analysis of Adenosquamous Carcinoma of the Pancreas

EJ Jordan, O Basturk, SD Leach, DS Klimstra, PJ Allen, MF Berger, ...

Comprehensive molecular profiling and analysis of mutual exclusivity of genetic aberrations (MEGA) of intra-and extrahepatic cholangiocarcinomas (IHC and EHC) evaluation of …

MA Lowery, R Ptashkin, E Jordan, MF Berger, A Zehir, NE Kemeny, ...

Current management and future directions in metastatic pancreatic adenocarcinoma

AM Varghese, MA Lowery, KH Yu, EM O'Reilly

Development of an advance care planning paradigm for advanced cancer: person-centered oncologic care and choices (P-COCC)

AS Epstein, EM O’Reilly, E Shuk, W Breitbart, MA Shah, M Ly, R Tayler, ...

Discussions of life expectancy and changes in illness understanding in patients with advanced cancer

AS Epstein, HG Prigerson, EM O’Reilly, PK Maciejewski